By Dean Seal


Shares of Soligenix Inc. gained 17% to 65 cents in premarket trading Tuesday after the company said regulators had cleared an investigational new drug application for a clinical trial examining its psoriasis treatment.

The company said the Food and Drug Administration had cleared the application for a Phase 2a trial designed to evaluate SGX302 as a topically applied treatment for mild to moderate psoriasis.

The trial will be a randomized, double-blind and placebo-controlled study of up to 32 adults with stable psoriasis covering between 2% and 30% of their bodies. Treatment will last for up to 18 weeks, Soligenix said.

Patient enrollment is expected to begin in the fourth quarter of 2022.


Write to Dean Seal at


(END) Dow Jones Newswires

June 28, 2022 08:12 ET (12:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.